A bioprocess engineering company called OmniBRx Biotechnologies Private Limited has secured $5 million Series-A funding from SIDBI Ventures and others.
Mar 2023, Gujarat [India] - A bioprocess engineering company called OmniBRx Biotechnologies Private Limited has secured $5 million Series-A funding from SIDBI Ventures and others. The money raised will help expand OmniBRx overseas and strengthen their innovative product portfolio of Single-use Bioreactors.
“Scalable and Efficient bioprocessing technologies, specifically the Single-use bioreactor platforms are in high demand worldwide for the production of vaccines and other biologicals. Innovation based technology solutions from OmniBRx has potential to meet these exponentially growing market demands of biologics and vaccines ”said Mr. Ravindra Patel, founder and CEO of OmniBRx Biotechnologies. “The CellBRx Single-use Bioreactors from OmniBRx are the world’s largest and most efficient vaccine manufacturing platform for large-scale vaccines and viral vector production. OmniBRx is also the creator of world’s first integrated seed train development platforms in close-loop sequentially programmed bioreactor systems” Ravindra added.
“With infusion of series-A funds, OmniBRx is all set to expand their business territories outside of India through subsidiaries and their authorized distributor networks. The company plans to expand their existing manufacturing facilities and strengthening their production capabilities to meet exponentially growing market demand of single-use bioprocessing technologies, added Mr Anandprakash Joshi, COO of OmniBRx Biotechnologies.
“The support provided by these world-class investors is an important milestone for our journey to transform the bioprocessing needs and practices of the industry and dramatically improve vaccine production capabilities of our valuable business partners, the biopharmaceuticals.” further added Mr Ravindra Patel.
Sajit Kumar, Sr. VP at SIDBI Venture Capital Limited quoted “We are happy to partner with OmniBRx. We believe that their focus and deep domain knowledge will help them to penetrate the global markets. This is our third investment out of “Ubharte Sitaare Fund”, fund for MSME’s focused on scaling up in the export markets. Wishing them all the best”.
About OmniBRx biotechnologies:
OmniBRx is an Ahmedabad based Bioprocess engineering company focused on design and development of novel single-use bioreactors (SUB’s) for cell culture based bioprocessing applications including the production of vaccines, viral vectors and gene therapies. The company was incorporated in 2016 and successfully launched their innovative products like CellBRx, SeedBRx and MiniBRx single-use Bioreactor platforms. Applications of OmniBRx innovative product range includes a wide range of biologics manufacturing, including: Cell therapy, gene therapy, recombinant protein, vaccine production, tissue engineering, stem cell therapy, and many more. Earlier, the company has received funding support from BIRAC-DBT (New Delhi) and Venture Centre (EDC, Pune).
About SIDBI Ventures:
SIDBI Venture Capital Limited (SVCL), incorporated in 1999, is an investment management company and a wholly owned subsidiary of SIDBI (www.sidbi.in), the Apex Financial Institution in India for the MSME sector. “Ubharte Sitaare Fund” is the eighth Fund set-up and managed by SVCL.